Clinical Trials Logo

Afibrinogenemia clinical trials

View clinical trials related to Afibrinogenemia.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT03920332 Completed - Clinical trials for Afibrinogenemia, Congenital

Pregnancy and Fibrinogen Disorders

FIBRINOGEST
Start date: September 1, 2019
Phase:
Study type: Observational

The aim of this observational study is to evaluate the prevalence of uncomplicated pregnancies in women suffering from congenital fibrinogen disorders (i.e, hypofibrinogenemia, dysfibrinogenemia, hypodysfibrinogenemia) as well as to describe pregnancies outcomes in such diseases.

NCT ID: NCT03484065 Completed - Clinical trials for Afibrinogenemia, Congenital

Quality of Life in Patients With Congenital Afibrinogenemia

QualyAFIB
Start date: June 2016
Phase:
Study type: Observational

The aim of this observational study is to evaluate the quality of life in patients with congenital afibrinogenemia using the Haemo-QoL SF for kids and the Haem-A-QoL for adult patients.

NCT ID: NCT02822599 Completed - Hypofibrinogenemia Clinical Trials

Human Fibrinogen Concentrate in Pediatric Cardiac Surgery

RiaSTAP
Start date: June 1, 2017
Phase: Phase 4
Study type: Interventional

The goal of the study is to determine whether the use of Human Fibrinogen Concentrate (RiaSTAP) will decrease blood loss and the need for component blood therapy in neonates and infants undergoing cardiopulmonary bypass.

NCT ID: NCT02427217 Completed - Clinical trials for Congenital Fibrinogen Deficiency

An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency

Start date: May 7, 2015
Phase: N/A
Study type: Observational

This is a multicenter, non interventional, retrospective cohort study with a prospective, observational follow-up component to investigate the safety and efficacy of FCH use in subjects with congenital fibrinogen deficiency. Data will be collected on the safety and efficacy of FCH as used for the treatment of acute bleeding episodes, routine prophylaxis and perioperative bleeding in these subjects. All subjects have received FCH and may continue to receive FCH at the discretion of the treating physician / Primary Investigator according to the standard of care at the participating study site.

NCT ID: NCT02408484 Completed - Clinical trials for Congenital Fibrinogen Deficiency

Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin in Paediatric Subjects With Fibrinogen Deficiency

Start date: December 2015
Phase: Phase 3
Study type: Interventional

This study will assess the efficacy of Octafibrin, a fibrinogen concentrate in in the on-demand treatment of spontaneous or traumatic bleeding episodes in paediatric patients less than 12 years of age.The planned study duration is up to 5 years. The study will be considered completed when a minimum of 6 subjects (i.e., at least 3 subjects aged between 0 and <6 years and 3 subjects aged between 6 and <12 years) have at least one documented bleeding episode and when in total a minimum of 2 surgical procedures have been performed. All patients will undergo a pharmacokinetic (PK) study after screening. This will have a duration of 14 days, after which a patient can be treated for a bleeding episode or planned surgical procedure when they occur.

NCT ID: NCT02281500 Completed - Clinical trials for Congenital Afibrinogenemia

Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia

IG0902
Start date: July 22, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The main objective of this study was to evaluate the pharmacokinetics (PK), efficacy, and safety of human plasma-derived fibrinogen concentrate FIB Grifols after a single-dose 70 milligrams/kilogram (mg/kg) body weight administration.

NCT ID: NCT02267226 Completed - Clinical trials for Congenital Fibrinogen Deficiency

Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery

Start date: September 2014
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the efficacy and safety of Octafibrin for on-demand treatment of acute bleeding in subjects with congenital fibrinogen deficiency.

NCT ID: NCT02094430 Completed - Clinical trials for Afibrinogenemia, Congenital

Human Fibrinogen Concentrate (FGTW) in Pediatric Patients With Congenital Fibrinogen Deficiency

Start date: January 2014
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of the study is to evaluate clinical pharmacology, efficacy and safety of FGTW in pediatric patients with congenital fibrinogen deficiency.

NCT ID: NCT02065882 Completed - Clinical trials for Congenital Afibrinogenemia

Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency

Start date: March 2013
Phase: Phase 3
Study type: Interventional

The purpose of the study is to investigate pharmacokinetics, efficacy and safety of BT524 in patients with congenital fibrinogen deficiency.

NCT ID: NCT01575756 Completed - Clinical trials for Congenital Fibrinogen Deficiency

Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap

Start date: June 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate pharmacokinetic properties, surrogate efficacy and safety of Octafibrin compared to Haemocomplettan® P/RiaSTAPTM in patients with congenital fibrinogen deficiency